Compare Incyte Corporation (INCY) vs Genmab A/S (GMAB) Stock

Genmab A/S (GMAB) offers the better valuation at 15.4x trailing P/E (23.2x forward), making it the more compelling value choice. Analysts rate Incyte Corporation (INCY) a "Buy" — based on 44 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Genmab A/S (GMAB) is the cheapest at 15.4x versus Incyte Corporation at 15.8x. On forward P/E, Incyte Corporation is actually cheaper at 13.4x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Incyte Corporation (INCY) delivered a total return of +27.2%, compared to -16.2% for Genmab A/S (GMAB). A $10,000 investment in INCY five years ago would be worth approximately $13K today (assuming dividends reinvested). Over 10 years, the gap is even starker: GMAB returned +138.4% versus INCY's +37.8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Genmab A/S (GMAB) is the lower-risk stock at 0.61β versus Incyte Corporation's 0.61β — meaning INCY is approximately 0% more volatile than GMAB relative to the S&P 500. On balance sheet safety, Incyte Corporation (INCY) carries a lower debt/equity ratio of 1% versus 3% for Genmab A/S — giving it more financial flexibility in a downturn.

Genmab A/S (GMAB) is the more profitable company, earning 36.4% net margin versus 25.0% for Incyte Corporation — meaning it keeps 36.4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GMAB leads at 31.1% versus 26.1% for INCY. At the gross margin level — before operating expenses — GMAB leads at 95.4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Incyte Corporation (INCY) trades at 13.4x forward P/E versus 23.2x for Genmab A/S — 9.7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GMAB: 37.6% to $40.50.

None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Genmab A/S (GMAB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.61), +138.4% 10Y return). Both have compounded well over 10 years (GMAB: +138.4%, INCY: +37.8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.